All trans retinoic acid (ATRA) is able to induce complete remission (CR) in almost all patients with acute promyelocytic leukemia (APL) through in vivo dierentiation of APL blasts. However, it cannot eliminate the leukemic clone and to be eective must be used in combination with anthracycline-based chemotherapy. Experience accumulated over the last 10 years has clearly shown that the combination of ATRA and chemotherapy gives better survival in newly diagnosed APL than chemotherapy alone because of fewer relapses and a higher CR rate experienced by these patients. It is also strongly suggested that maintenance treatment with ATRA, and possibly in combination with low-dose chemotherapy, can further reduce the incidence of relapse. Overall, more than 90% of patients with newly diagnosed APL can achieve CR and about 75% can be cured by the combination of ATRA and chemotherapy. Oncogene (2001) 20, 7140 ± 7145.
Acute promyelocytic leukemia (APL) was ®rst de®ned by a speci®c morphological feature and by a bleeding diathesis. The ®rst description (Hillestad, 1957) distinguished APL from acute non-lymphoblastic leukemia, while the coagulopathy responsible of the diuse hemorrhage was de®ned as an acquired a®brinemia, probably due to a ®brinolysis (Caen et al., 1957 (Caen et al., , 1959 . A series of 20 patients con®rmed the speci®c entity of the disease .
The frequency of de novo APL is estimated to be 8 ± 15% of all acute non-lymphoblastic leukemia, with a mean incidence of 2 ± 3 cases per million inhabitants per year. The frequency is higher (15 ± 20%) in Southern Europe (Italy, Spain, Portugal) compared with Central Europe (7% in Germany). A high incidence is reported in Latin American countries, accounting for 30% of acute non-lymphoblastic leukemia (Douer et al., 1996) . Both sexes are equally vulnerable (Avvisati et al., 1991) and APL is uncommon in children. An increasing number of cases have been reported as therapy-related APL (t-APL), particularly after intensive chemotherapy with cyclosphosphamide, doxorubicin, etoposide and mitoxanthrone in the treatment of non-Hodgkin's lymphoma (Beaumont et al., 2000) .
Two features speci®cally de®ne the disease: the morphology of the malignant cells and the pathology of coagulation (coagulopathy). The classical hypergranular APL (Bennett et al., 1976 ) with a typically low white blood cell count, termed M3 in the FAB classi®cation, is diagnosed by the morphological aspect of cells in bone marrow smears. The majority of cells are abnormal promyelocytes bearing numerous large granules and Auer rods (linear package of granules), sometimes grouped in faggots. A microgranular variant (M3v) of the disease is characterized by a bilobed nucleus and very small granules that are not visible with light microscopy (Bennett et al., 1980) . Patients with M3v have a high white blood cell count and a poor prognosis (early death and risk of relapse).
Coagulopathy is de®ned by a severe hypo®brinogen-openia with high levels of ®brinogen/®brin degradation products. The controversy on the origin of low level of ®brinogen between primary ®brinolysis and disseminated intravascular coagulopathy (DIC) is still open . On one hand, the primary ®brinolysis theory is supported by the high level of annexin II detected on APL leukemic cells (and not on other types of leukemic cells). Annexin II is a cell surface receptor for plasminogen, as well as one of its activators, the tissue plasminogen activator, tPA (Menell et al., 1999) . On the other hand, the DIC theory is supported by the presence of tissue factor release by APL cells (Zhu et al., 1999) . Tissue factor serves to initiate interaction between coagulation and Factor VII. This controversy has led to two therapeutic approaches providing treatment that uses either heparin against DIC, or epsilon amino caproic acid against ®brinolysis (Rodeghiero et al., 1990) . The reversion of the bleeding diathesis by ATRA demonstrates that both mechanisms co-exist. However the bleeding diathesis is mainly related to primary ®brinolysis since the normalization of clinical features and the level of ®brinogen during the ATRA treatment follows the disappearance of ®brinolysis, while the DIC persists (Dombret et al., 1995) .
APL has been con®rmed as a distinct disease by the presence of an abnormal cytogenetic feature. First considered as a partial deletion of chromosome 17 (Golomb et al., 1976) , the abnormality was recognized as a balanced and reciprocal translocation, t(15;17), between the long arms of chromosomes 15 and 17 (Rowley et al., 1977) , which is consistently associated with the disease (Larson et al., 1984) .
The disease is thus de®ned by a trilogy including: morphological features (FAB M3); coagulopathy associated with a hypo®brinogenopenia; and the speci®c translocation t(15;17).
Before the advent of ATRA-based therapy, APL was thought to be particularly sensitive to anthracyclines (Bernard et al., 1973) . The remission rate has progressively improved (from 50 to 80%) during the two last decades due to a better control of bleeding diathesis using intensive platelet support. Failure to achieve CR is due to early death and is mainly attributable to central nervous system bleeding (10%) and to a resistance to anthracyclines (10%). Bleeding diathesis was usually exacerbated by chemotherapy. In contrast to the situation in other acute non-lymphocytic leukemia, in APL cytosine arabinoside (Ara-C) at standard doses does not appear to be bene®cial in combination with anthracyclines (Avvisati, 1999) . Among patients who achieved a CR, only 35% have had a long-term survival.
All trans retinoic acid treatment in APL Retinoids are able to induce a terminal dierentiation of leukemic cell lines, such as HL60 and U937, and of short-term culture APL cells from humans (Breitman et al., 1981; ). An informal discussion between us (Degos and Wang, Paris, 1985) on dierentiation therapy of APL using retinoids, pointed out the fact that the only available retinoid in Europe, the ethyl ester retinoid (etritinate) is not eective on APL cells . In fact the dierentiation eect on fresh cells is restricted to patients with the APL subtype of non-lymphoblastic leukemia and the sensitivity of the malignant cells depends on the speci®c derivative, with ATRA being the most ecient drug .
All trans retinoic acid was produced in ShanghaõÈ and ®rst used to treat patients there (Huang et al., 1988) . Following a collaborative meeting in ShanghaõÈ in 1987, the Chinese drug was kindly provided to subsequently treat French patients .
Differentiative effect obtained with ATRA alone in APL
Treatment with ATRA (daily dose of 45 mg/m 2 ) was proposed for newly diagnosed patients in ShanghaõÈ (Huang et al., 1988) and for patients in ®rst or subsequent relapse in Paris , with the CR rate reaching 90%. The clinical features were unusual for a chemotherapy inducing a CR of leukaemia. Instead of the initial worsening observed with conventional chemotherapy, coagulopathy rapidly improved. No primary resistance, no aplastic phase, no hairless, and few infectious episodes were observed. The most remarkable features was the progressive change of malignant cells in bone marrow, with signs of their terminal dierentiation and with Auer rods being sometimes observed in mature cells . The dierentiation process was con®rmed by serial¯uorescence in situ hybridization (FISH) and clonality was demonstrated using X chromosomelinked polymorphism (Warrell et al., 1991) . Clonal malignant cells carrying the t(15;17) translocation are replaced by polyclonal hematopoiesis. Correction of neutrophils and platelets occurred ®rst, after 1 month of treatment, while low hemoglobin levels and monocytopenia persisted for a few days after treatment, most likely in relation to the inhibitory eect of retinoic acid on BFU E and CFU M (MicleÂ a and Chomienne, 1994) .
However treatment with ATRA alone showed two adverse eects: one during and one following treatment. An activation of leukocytes inducing an increase in white blood cell count is observed during treatment with ATRA alone , and onethird of patients develop the so-called`ATRA syndrome' . Following treatment with ATRA alone, patients experience an induction of a secondary resistance to ATRA.
The leukocyte activation syndrome combines fever, respiratory distress, weight gain, pleural or pericardial eusions and, sometimes, renal failure. The incidence of this syndrome is lower in China compared with Europe or America and the syndrome is frequently preceded by an increase in WBC counts in peripheral blood. The pathophysiology is not clearly understood and appears to be related to cytokine release by dierentiating cells (Dubois et al., 1994) . Two approaches have been attempted to counteract this syndrome: (1, European attitude) is to prevent the syndrome using chemotherapy when WBC counts increase; and (2, American attitude) is to treat the syndrome with high-dose intravenous corticosteroids. The current consensus is to use chemotherapy in combination with ATRA and to add corticosteroids either from the onset of treatment, if patients have a high WBC count, or when patients show symptoms of ATRA syndrome during the treatment.
Secondary resistance occurs in all patients treated with ATRA . Thus, patients receiving ATRA alone achieved CR for only a short time, usually relapsing within 6 months. Patients treated with ATRA become refractory to this treatment for a period of 6 ± 12 months and the acquired resistance is usually reversible after this period. Since all patients acquire a resistance and because that the resistance is usually reversible, it appears that a secondary genetic change is not involved in this process, in contrast to the phenomenon occurring in arti®cial ATRA-resistant cell lines.
This observed resistance is likely to be related to feedback mechanisms that aim at reducing ATRA concentrations in the organism. A signi®cant decrease of ATRA levels in plasma is observed after only few days of treatment and ATRA remains at lower, sometimes undetectable, levels even if the dose is doubled (Muindi et al., 1992) . On one hand, ATRA treatment increases the activity of cytochrome P450 implicated in the catabolism of ATRA itself, which reduces the plasma level of the drug (Muindi et al., 1992) , and on the other, ATRA down-regulates the transcription of the cytoplasmic retinoic acid binding protein II (CRABP II), thereby inducing a reduction of nucleic concentration of the drug (Cornic et al., 1992) .
ATRA in combination with chemotherapy: a step towards the cure of APL The occurrence of secondary resistance to ATRA in APL patients led us to administer a new treatment combining ATRA with intensive chemotherapy.
Non randomized studies In the ®rst studies (Fenaux et al., 1992) , 26 newly diagnosed cases of APL, treated with ATRA (45 mg/m 2 /day) until CR, followed by three courses of chemotherapy (daunorubicin and ara-C) were compared with an historical control group treated with chemotherapy alone. Initial results showed that ATRA followed by chemotherapy dramatically reduces the number of relapses (occurring within 24 months after the onset of the disease). These results have now been largely con®rmed Kanamaru et al., 1995) .
Randomized trials: ATRA followed by chemotherapy An European trial (APL 91) comparing three courses of chemotherapy (daunorubicin and ara-C) to initial ATRA treatment followed by the same chemotherapy in newly diagnosed APL patients was prematurely stopped after 18 months because the event free survival (EFS) was signi®cantly better in the ATRA group. The last interim analysis con®rmed the higher actuarial EFS (63 versus 17% at 4 years P50.0004), mainly due to a reduction in relapse rate (31 versus 78% at 4 years P50.03) (Fenaux et al., 1993 . In a three-year American inter-group study, started in 1992 and closed in 1995, three courses of chemotherapy were compared with ATRA treatment followed by two courses of chemotherapy (Tallman et al., 1997) , the incidence of relapse was signi®cantly reduced in patients who received ATRA (33 versus 68% at 3 years P50.01).
Randomized trials: ATRA given simultaneously with chemotherapy Initially ATRA was used alone until CR followed by chemotherapy. The European group (APL 93 trial) compared two combination regimens including ATRA and chemotherapy, ATRA being given either prior to chemotherapy or simultaneously with chemotherapy. In the latter combination ATRA was started 3 days before chemotherapy in order to maintain the bene®cial eect on coagulation disorders. Relapses at 2 years are signi®cantly less frequent (6 versus 16%) when ATRA is given simultaneously to chemotherapy (Fenaux et al., 1999) .
Treatment of APL after remission
In 1995, the Chinese Cooperative Study Group retrospectively summarized 5-year survival probability (5SP) in 423 APL patients treated with ATRA as induction of remission, followed by ATRA alone or ATRA plus chemotherapy as maintenance therapy. The median follow-up period was 50 months. The post-remission protocols were divided into four groups: (1) group A (n=29) given ATRA alone; (2) group B (n=217) given standard chemotherapy alone (Daunorubicin, homoharringtonine and Ara-C); (3) group C (n=107) given alternating treatment with chemotherapy and ATRA; and (4) group D (n=70) given sequentially with standard chemotherapy, ATRA and methotrexate (MTX) each for one month. The 5SP was 0.18+0.08, 0.51+0.05; 0.68+0.03 and 0.71+0.06, respectively. It seems likely that the alternating use of chemotherapy and ATRA could yield a longer survival time .
Two randomized studies (Tallman et al., 1997; Fenaux et al., 1999) strongly suggest that maintenance treatment with ATRA has a bene®cial eect in newly diagnosed APL. The American inter-group trial (Tallman et al., 1997) compared continuous ATRA treatment as maintenance (45 mg/m 2 /day) for one year with no maintenance. The frequency of relapse was reduced in patients who received ATRA (10 of 46 versus 24 of 54 patients). However liver toxicity limits the use of continuous maintenance with ATRA and patients who received no ATRA during induction therapy also bene®ted from ATRA maintenance.
The European APL group (APL 93 trial) (Fenaux et al., 1999) randomized patients who achieved CR between into arms with no maintenance and maintenance with ATRA 15 days every 3 months, continuous low-dose chemotherapy with 6-mercaptopurine and MTX, or both (ATRA and low-dose chemotherapy) for 2 years using a 2x2 factorial design. The frequency of relapse at 2 years was reduced in patients who received ATRA compared with those who did not (13 versus 25% P40.02) and was also reduced in patients who received low-dose chemotherapy compared with those who did not (11 versus 27% P50.03). An additive eect of low-dose chemotherapy and ATRA maintenance therapies was also observed (7% of relapse at 2 years). Furthermore, patients with poor prognosis because of high of blood cell counts at diagnosis seemed to bene®t particularly from both lowdose chemotherapy and ATRA maintenance (10 versus 30% of relapse rate at 2 years).
Is APL a curable disease? The conclusion of these randomized trials suggests that APL patients should be treated with ATRA and chemotherapy including anthracyclines simultaneously, as induction treatment; two courses of chemotherapy (including anthracyclines or similar drugs), for consolidation; and ATRA in combination with low-dose chemotherapy for 2 years, as maintenance therapy. Under these conditions we can achieve a CR rate over 90% and a relapse rate lower than 10% at year 2. If few delayed relapses occur we hope that more than 75% of APL patients will actually be cured.
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Prognostic factors
White blood cell count
High white blood cells counts at diagnosis (more than 5000 ± 10 000 mm 3 , according to the various group protocols) increase the risk of early mortality and relapses. The M3v hypogranular form is often associated with a high white blood cell count which increase the risks of leukocyte activation syndrome and relapse. Simultaneous administration of ATRA, chemotherapy with dexamethasone reduces the risk of leukocyte activation syndrome and mortality. In addition maintenance therapy (ATRA plus chemotherapy) reduces the risk of relapse (Fenaux et al., 1999) .
Age
Patients older than 65 years have a higher risk of early death (17 versus 6% in younger patients) (Fenaux et al., 1999) . New treatment combinations, such as the association of ATRA and arsenic trioxide (AS 2 0 3 ), which exclude or reduce anthracyclines, have yet to be tested.
Other types of APL
Therapy-related APL (t-APL) has a similar outcome as non t-APL (Beaumont et al., 2000) . Several other translocations including retinoic acid receptor alpha (RARa) as a partner are actually registered. Some are sensitive to ATRA, other are not (see Table 1 ). In case of the t(11;17) translocation involving the PLZF-RARa fusion protein, G-CSF appears to be bene®cial when associated with ATRA (Jansen et al., 1999) .
Immunophenotype APL blasts have a dierent immunophenotype from those of other forms of AML. Although all AML have a positive expression of CD13 and CD33, APL blasts lack HLA ± DR antigens and usually have negative expression of CD34 and CD7, indicating that they derive from a more mature progenitor cell than other AML cells. Sometimes they also carry lymphocyte markers such as the B-cell marker, CD19 or the T-cell marker, CD2. This latter marker is mainly found in cases of M3v and in patients with PML ± RARa/bcr3 breakpoint. CD19 seems to be associated with high white blood cell counts (Guglielmi et al., 1998) . The eect of presence or not of CD56 in the survival is suspected (Murray et al., 1999; Ferrara et al., 2000) .
Karyotype
and molecular biology Additional karyotype abnormalities do not appear to in¯uence prognosis in APL (Schoch et al., 1996; Slack et al., 1997) . The type of PML ± RARa isoform has been suggested as a pronostic factor, with bcr1, the longest isoform, giving a better pronostic index (Vahdat et al., 1994) . In a recent clinical trial using ATRA plus chemotherapy as maintenance therapy, the bcr type is no longer considered to be a pronostic factor (Fenaux et al., 1999) .
Molecular remission is an endpoint for a better survival. However the de®nition of molecular remission depends upon the sensitivity of the RT ± PCR technique. Quantitative RT ± PCR will provide the threshold value for prognostic estimates after combination chemotherapy/ATRA treatment. Some patients have shown a delayed molecular CR without early relapse (personal observation). A conversion from negative to positive PCR is consistently associated with subsequent hematological relapse (Biondi et al., 1992; Castaigne et al., 1992; Huang et al., 1993; Lo Coco et al., 1999) .
Sensitivity to ATRA using short-term cultures of fresh bone marrow cells The sensitivity of the leukemic clone to ATRA at diagnosis is an independent criterion of long-term patient outcome, in terms of better EFS, fewer relapses and better overall survival (Cassinat and Chomienne, 2001) . It has been demonstrated previously that primary cultures of blast cells are correlated with CR . Thus, the ecacy of dierentiation therapy in vivo ecacy would appear to be correlated with in vivo sensitivity, in contrast to classical chemotherapy where in vivo experiments cannot predict in vivo results.
Conclusion

ATRA in APL: a first model for multiple process
The addition of ATRA to traditional chemotherapy for APL has opened a new door for curing one of the most severe type of acute leukemia. ATRA is the ®rst model of ecient dierentiation therapy for malignant disease. ATRA induces a terminal dierentiation for EPO, G-CSF, IL2, IL3 and IL7
Oncogene All trans retinoic acid in acute promyelocytic leukemia L Degos and ZY Wang followed by a natural apoptosis of malignant cells and is, thus, the leading drug for modifying the biological process of malignant cells. Other cell modi®ers such as arsenic trioxide for APL or antikinase for chronic myeloid leukemia are currently being investigated. In addition, because ATRA is eective essentially in the leukemia-bearing speci®c chromosome aberration t(15;17) with PML ± RARa fusion gene, the treatment of APL with ATRA constitutes a successful model for gene-targeting therapy.
ATRA in APL provides the opportunity to improve our understanding of leukemogenesis: arrest of dierentiation through nuclear receptors RARa, linked to corepressors and coactivators, and senescence and apoptotic disorders through PML.
The eect of ATRA in APL enables us to determine the nuclear components either at the transcriptional regulation level through the RARa receptor, or at the level of intranuclear trac, through PML linked with several molecules in the nuclear bodies.
ATRA and arsenic are now available for the treatment of APL. These two drugs have dierent mechanisms of action: one acting on RARa, the other on PML. Both remove the oncogenic molecule PML ± RAR and the two abnormalities, namely dierentiation arrest and defective apoptosis. The cure of one of the most dramatic forms of leukemia, APL, is now within reach.
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